Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CURXthis companyCuranex Pharmaceuticals Inc Common Stock	$5.94	-2.22×	0.83×	0×	-1.15×	-44.2%	0.0%	0.0%	0.0%	-37.7%	-36.7%	-111.9%	0.03×	1.12×	-496.55×	81.93×	0.0%	2	10.38	2	B-
ASBPAspire Biopharma Holdings, Inc.	$8.45	-9.67×	-37.14×	38,181.4×	-20.93×	-107.4%	-1.9%	-312016.9%	-394725.1%	383.9%	395.3%	-2.1%	-0.22×	-0.03×	-2.27×	0.17×	0.0%	5	-3.49	2	C
CRISCuris, Inc.	$0.74	-1.7×	2.38×	1.38×	-1.83×	-1429.1%	99.5%	-348.4%	-80.3%	-138.8%	-464.7%	-209.4%	0.3×	0.66×	-15.06×	0.49×	0.0%	0	-98.45	1	C-
DAREDare Bioscience, Inc.	$0.66	-1.61×	75.9×	209.43×	-18.58×	-72.9%	-137.5%	-1315.5%	-1300.7%	-471.4%	-124.5%	-4.8%	0.93×	2.12×	-16.47×	1.14×	0.0%	2	-13.47	2	C+
LGVNLongeveron Inc.	$1.99	-0.39×	1.57×	7.42×	-0.24×	-823.6%	67.0%	-1942.2%	-1893.6%	-400.1%	-341.0%	-212.4%	0.15×	0.18×	0×	1.33×	0.0%	2	-16.73	2	C
PALIPalisade Bio, Inc.	$1.23	-7.83×	1.01×	0×	0.15×	113.1%	0.0%	0.0%	0.0%	-13.0%	-13.9%	-8.3%	0×	7.95×	-1,805.6×	28.95×	0.0%	4	19.43	2	C
Peer median	—	-1.7×	1.57×	7.42×	-1.83×	-107.4%	0.0%	-1315.5%	-1300.7%	-138.8%	-124.5%	-8.3%	0.15×	0.66×	-15.06×	1.14×	0.0%	2	-13.47	2	—